MorphoSys AG (MORG.DE)
MORG.DE on Xetra
94.55EUR
9:21am BST
94.55EUR
9:21am BST
Change (% chg)
€-1.85 (-1.92%)
€-1.85 (-1.92%)
Prev Close
€96.40
€96.40
Open
€95.95
€95.95
Day's High
€95.95
€95.95
Day's Low
€94.50
€94.50
Volume
21,524
21,524
Avg. Vol
146,348
146,348
52-wk High
€124.90
€124.90
52-wk Low
€76.45
€76.45
About
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)
Overall
| Beta: | 0.86 |
| Market Cap(Mil.): | €3,069.33 |
| Shares Outstanding(Mil.): | 31.84 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MORG.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 93.91 | 35.38 |
| EPS (TTM): | -1.90 | -- | -- |
| ROI: | -13.83 | 7.62 | 11.72 |
| ROE: | -14.71 | 8.12 | 16.38 |
German stocks - Factors to watch on May 22
BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday:
German stocks - Factors to watch on April 30
BERLIN, April 30 The following are some of the factors that may move German stocks on Tuesday:
BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
German biotech group Morphosys seeks European partner for debut drug
FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.
German stocks - Factors to watch on Jan. 28
BERLIN, Jan 28 The following are some of the factors that may move German stocks on Monday:
Estimates